Associated tags: Medication, Neurology, Research, Pharmaceutical industry, Senior, Patient, Discovery, Drug discovery, Antibody, Health
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA, ONO, JAPAN, UNITED KINGDOM, MASSACHUSETTS, ASIA PACIFIC, BOSTON, MA, US, SAN FRANCISCO, LEBANON, USA, ENGLAND, UK, LONDON, HEIDELBERG, GERMANY
CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company. The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
Key Points:
- CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company.
- The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
- The Golden Ticket awards provide two promising early-stage R&D companies lab space and mentorship, components that are vital to the success of promising life science businesses.
- The competition seeks proposals from startup companies in the oncology, immunology, neurology, and specialty areas.
TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. ("Ono ").
Key Points:
- Under the terms of the agreement, Ono and PRISM will jointly create a development candidate for Ono's oncology target using PepMetics® technology.
- Upon identification of the development candidate, PRISM will license its rights to Ono for clinical development and commercialization.
- "We highly appreciate PRISM's PepMetics® technology in PPI drug discovery", said Seishi Katsumata, Executive Director, Discovery & Research of Ono.
- "We are very excited to enter into this collaboration with Ono who has a history of creating innovative drugs.
Oncology,
Health,
Research,
Pharmaceutical,
Science,
Biotechnology,
Discovery,
Central nervous system,
Entrepreneurship,
Ono Pharmaceutical,
Partnership,
Patient,
CNS,
Doctor of Philosophy,
Protein,
Senior,
Protein folding,
Drug development,
Pharmaceutical industry Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders.
Key Points:
- Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders.
- Ono Pharmaceutical plans to harness this technology to address some of the most challenging aspects of CNS drug development by targeting proteins involved in complex neurological pathways.
- Together, we aim to unlock new therapeutic possibilities for patients worldwide,” commented Lidia Pieri, PhD, Co-Founder and Chief Executive Officer of Sibylla Biotech.
- “I am honored to collaborate with the Ono Pharmaceutical team, whose rich history, expertise and culture I greatly appreciate, and all of us at Sibylla look forward to working closely with them.”
Discovery,
Harvard Medical School,
Research,
Neurology,
Ono Pharmaceutical,
Drug discovery,
Patient,
Harvard University,
Senior,
OTD,
Pharmaceutical industry OSAKA, Japan, March 11, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University (Cambridge, MA, USA; "Harvard") aiming at validating novel therapeutic targets.
Key Points:
- OSAKA, Japan, March 11, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University (Cambridge, MA, USA; "Harvard") aiming at validating novel therapeutic targets.
- Working together with Harvard's Office of Technology Development (OTD), Ono will support and fund research projects that are jointly selected.
- With the combined expertise and resources of both Ono and Harvard, this strategic alliance will promote our innovative drug discovery efforts.
- "We are pleased to work together with Harvard University, a leading institution developing cutting-edge technologies and advancing research through strategic alliances such as this one," stated Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research at Ono Pharmaceutical.
Retrieved on:
Wednesday, February 21, 2024
Senior,
Algorithm,
AI,
Generative,
Drug discovery,
Discovery,
Synthetic media,
Patient,
Machine learning,
Research,
Pharmaceutical industry "InveniAI is thrilled to partner with Ono, a company renowned for its commitment to innovation in drug discovery and development. Our collaboration signifies the merging of our collective expertise and cutting-edge technologies aimed at expediting the identification of de-risked product opportunities," said Krishnan Nandabalan, Ph.D., President and CEO at InveniAI, LLC. "Our unwavering commitment to enhancing patient outcomes drives us to consistently integrate technological innovation into our processes. A testament to this is our recent incorporation of large language modules, and generative AI culminating in the creation of ChatAlphaMeldä---a game-changing tool designed for the seamless utilization of advanced technology tools across the organization."
Key Points:
- OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; "InveniAI"), to identify novel therapeutic targets by leveraging cutting-edge InveniAI's artificial intelligence (AI) and machine learning (ML).
- Ono will conduct validation studies to confirm the hypotheses for multiple therapeutic target candidates identified based on InveniAI's drug discovery hypotheses.
- "Through this collaboration, the efficiency of drug discovery research will be greatly improved, and we hope to provide innovative therapeutic options to patients worldwide."
- "InveniAI is thrilled to partner with Ono, a company renowned for its commitment to innovation in drug discovery and development.
Retrieved on:
Wednesday, February 14, 2024
OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; "Shattuck") to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.
Key Points:
- OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; "Shattuck") to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.
- Under the terms of the agreement, Shattuck will generate fusion proteins for certain targets using its proprietary protein engineering technology and provide Ono with drug candidates for further optimization and clinical development.
- Ono will have an exclusive option right to develop and commercialize multiple potential drug candidates to be created through this collaboration worldwide.
- This collaboration aligns with our strategy to unlock further value from our bifunctional fusion protein platform and scientific expertise."
Retrieved on:
Wednesday, February 14, 2024
HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
Key Points:
- HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
- Under the terms of the agreement, Ono has obtained an option to in-license NM49 from Numab for global development and commercialization, with Numab retaining an option to co-develop and commercialize in the United States.
- “This important partnership marks our third collaboration with Ono and the first one where Numab has the option to co-develop and commercialize in the United States.
- We are thrilled to continue working with Ono on developing new high impact multi-specific therapeutics for cancer patients,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.
Retrieved on:
Tuesday, February 13, 2024
Senior,
Autoimmune disease,
Ono Pharmaceutical,
Discovery,
Inflammation,
Protein engineering,
Patient,
Autoimmunity,
Research,
Cancer,
Pharmaceutical industry Shattuck will lead discovery research of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck’s pipeline of bifunctional fusion proteins, and Ono will cover all of Shattuck’s associated research and development expenses.
Key Points:
- Shattuck will lead discovery research of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck’s pipeline of bifunctional fusion proteins, and Ono will cover all of Shattuck’s associated research and development expenses.
- Shattuck granted to Ono an exclusive option to develop and commercialize multiple products resulting from the collaboration agreement.
- “We have prioritized autoimmune and inflammatory diseases for a select group of preclinical pipeline candidates as we continue to expand into areas of high unmet need.
- “We hope to add bifunctional fusion proteins discovered and developed by Shattuck into our portfolio to bring innovative drugs for patients suffering from autoimmune and inflammatory diseases as soon as possible.”
OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
Key Points:
- OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
- For details, please refer to the following BioMed X press release and application guidelines for the research project:
BioMed X's press release dated December 19, 2023:
OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
Key Points:
- OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
- For details, please refer to the following BioMed X press release and application guidelines for the research project:
BioMed X's press release dated December 19, 2023:
